-
1
-
-
0028169718
-
The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology
-
Sears MR, Taylor DR. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf 1994;11:259-283.
-
(1994)
Drug Saf
, vol.11
, pp. 259-283
-
-
Sears, M.R.1
Taylor, D.R.2
-
3
-
-
0028887981
-
End of the New Zealand asthma mortality epidemic
-
Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995;345:41-44.
-
(1995)
Lancet
, vol.345
, pp. 41-44
-
-
Pearce, N.1
Beasley, R.2
Crane, J.3
Burgess, C.4
Jackson, R.5
-
4
-
-
33144476873
-
The salmeterol multicenter asthma research trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
-
DOI 10.1378/chest.129.1.15
-
Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26. (Pubitemid 43265239)
-
(2006)
Chest
, vol.129
, Issue.1
, pp. 15-26
-
-
Nelson, H.S.1
Weiss, S.T.2
Bleecker, E.K.3
Yancey, S.W.4
Dorinsky, P.M.5
-
5
-
-
31344475020
-
-
Center for Drug Evaluation and Research. Silver Spring, MD: FDA/CDER; November 18, (updated May 15, 2006; accessed April 10, 2009). Available from
-
U.S. Food and Drug Administration/Center for Drug Evaluation and Research. FDA public health advisory: Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder) [Internet]. Silver Spring, MD: FDA/CDER; November 18, 2005 (updated May 15, 2006; accessed April 10, 2009). Available from: http://www.fda.gov/CDER/Drug/ advisory/LABA.htm
-
(2005)
FDA Public Health Advisory: Serevent Diskus (Salmeterol Xinafoate Inhalation Powder), Advair Diskus (Fluticasone Propionate & Salmeterol Inhalation Powder), Foradil Aerolizer (Formoterol Fumarate Inhalation Powder) [Internet]
-
-
-
6
-
-
33747761653
-
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: A randomised controlled, double-blind study
-
DOI 10.1016/S0140-6736(06)69284-2, PII S0140673606692842
-
Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-753. (Pubitemid 44279053)
-
(2006)
Lancet
, vol.368
, Issue.9537
, pp. 744-753
-
-
Rabe, K.F.1
Atienza, T.2
Magyar, P.3
Larsson, P.4
Jorup, C.5
Lalloo, U.G.6
-
7
-
-
33344471388
-
Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomized, double-blind trial
-
DOI 10.1378/chest.129.2.246
-
Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, Lier PA, Jorup C. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246-256. (Pubitemid 43289841)
-
(2006)
Chest
, vol.129
, Issue.2
, pp. 246-256
-
-
Rabe, K.F.1
Pizzichini, E.2
Stallberg, B.3
Romero, S.4
Balanzat, A.M.5
Atienza, T.6
Lier, P.A.7
Jorup, C.8
-
8
-
-
44949194776
-
Regular treatment with formoterol for chronic asthma: Serious adverse events
-
CD006923
-
Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; (4):CD006923.
-
(2008)
Cochrane Database Syst Rev
, Issue.4
-
-
Cates, C.J.1
Cates, M.J.2
Lasserson, T.J.3
-
9
-
-
44949194776
-
Regular treatment with salmeterol for chronic asthma: Serious adverse events
-
CD006363
-
Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; (3):CD006363.
-
(2008)
Cochrane Database Syst Rev
, Issue.3
-
-
Cates, C.J.1
Cates, M.J.2
-
10
-
-
58849139194
-
Long-acting beta-agonists: A review of formoterol safety data from asthma clinical trials
-
Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: A review of formoterol safety data from asthma clinical trials. Eur Respir J 2009;33:21-32.
-
(2009)
Eur Respir J
, vol.33
, pp. 21-32
-
-
Sears, M.R.1
Ottosson, A.2
Radner, F.3
Suissa, S.4
-
11
-
-
57349199462
-
The safety of long acting β-agonists among patients with asthma using inhaled corticosteroids: Systematic review and metaanalysis
-
Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, Cheng J, Bala M, Schunemann HJ, et al. The safety of long acting β-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008;178:1009-1016.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 1009-1016
-
-
Jaeschke, R.1
O'Byrne, P.M.2
Mejza, F.3
Nair, P.4
Lesniak, W.5
Brozek, J.6
Thabane, L.7
Cheng, J.8
Bala, M.9
Schunemann, H.J.10
-
12
-
-
33745306721
-
Meta-analysis: Effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths
-
Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-912. (Pubitemid 46768131)
-
(2006)
Annals of Internal Medicine
, vol.144
, Issue.12
, pp. 904-912
-
-
Salpeter, S.R.1
Buckley, N.S.2
Ormiston, T.M.3
Salpeter, E.E.4
-
14
-
-
0027980288
-
Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma
-
Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994;7:1602-1609. (Pubitemid 24294244)
-
(1994)
European Respiratory Journal
, vol.7
, Issue.9
, pp. 1602-1609
-
-
Suissa, S.1
Blais, L.2
Ernst, P.3
-
15
-
-
58849160015
-
Safety of long-acting beta-agonists: Urgent need to clear the air remains
-
Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J 2009;33:3-5.
-
(2009)
Eur Respir J
, vol.33
, pp. 3-5
-
-
Beasley, R.1
Martinez, F.D.2
Hackshaw, A.3
Rabe, K.F.4
Sterk, P.J.5
Djukanovic, R.6
-
16
-
-
0026011647
-
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
-
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
-
(1991)
N Engl J Med
, vol.324
, pp. 781-788
-
-
Echt, D.S.1
Liebson, P.R.2
Mitchell, L.B.3
Peters, R.W.4
Obias-Manno, D.5
Barker, A.H.6
Friedman, L.7
Greene, H.L.8
-
17
-
-
0030612187
-
2-agonists prevent Th1 development by selective inhibition of interleukin 12
-
Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, Self C, Sinigaglia F. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513-1519. (Pubitemid 27425778)
-
(1997)
Journal of Clinical Investigation
, vol.100
, Issue.6
, pp. 1513-1519
-
-
Panina-Bordignon, P.1
Mazzeo, D.2
Di Lucia, P.3
D'Ambrosio, D.4
Lang, R.5
Fabbri, L.6
Self, C.7
Sinigaglia, F.8
-
19
-
-
0034027301
-
Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma
-
Aldridge RE, Hancox RJ, Taylor DR, Cowan JO, Winn MC, Frampton CM, Frampton CM, Town GI. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000;161:1459-1464. (Pubitemid 30329012)
-
(2000)
American Journal of Respiratory and Critical Care Medicine
, vol.161
, Issue.5
, pp. 1459-1464
-
-
Aldridce, R.E.1
Hancox, R.J.2
Taylor, D.R.3
Cowan, J.O.4
Winn, M.C.5
Frampton, C.M.6
Town, G.I.7
-
20
-
-
0035938606
-
2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial
-
Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583-2593. (Pubitemid 32479898)
-
(2001)
Journal of the American Medical Association
, vol.285
, Issue.20
, pp. 2583-2593
-
-
Lazarus, S.C.1
Boushey, H.A.2
Fahy, J.V.3
Chinchilli, V.M.4
Lemanske Jr., R.F.5
Sorkness, C.A.6
Kraft, M.7
Fish, J.E.8
Peters, S.P.9
Craig, T.10
Drazen, J.M.11
Ford, J.G.12
Israel, E.13
Martin, R.J.14
Mauger, E.A.15
Nachman, S.A.16
Spahn, J.D.17
Szefler, S.J.18
-
22
-
-
0024415103
-
The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness
-
Lai CK, Twentyman OP, Holgate ST. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am Rev Respir Dis 1989;140:917-923. (Pubitemid 19259487)
-
(1989)
American Review of Respiratory Disease
, vol.140
, Issue.4
, pp. 917-923
-
-
Lai, C.K.W.1
Twentyman, O.P.2
Holgate, S.T.3
-
23
-
-
27644565667
-
2-adrenergic receptor function and regulation
-
DOI 10.1513/pats.200504-027SR
-
McGraw DW, Liggett SB. Molecular mechanisms of beta2-adrenergic receptor function and regulation. Proc Am Thorac Soc 2005;2:292-296. (discussion 311-2). (Pubitemid 41566938)
-
(2005)
Proceedings of the American Thoracic Society
, vol.2
, Issue.4
, pp. 292-296
-
-
McGraw, D.W.1
Liggett, S.B.2
-
24
-
-
34248192733
-
Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation
-
DOI 10.1172/JCI30489
-
McGraw DW, Elwing JM, Fogel KM, Wang WC, Glinka CB, Mihlbachler KA, Rothenberg ME, Liggett SB. Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. J Clin Invest 2007;117:1391-1398. (Pubitemid 46718427)
-
(2007)
Journal of Clinical Investigation
, vol.117
, Issue.5
, pp. 1391-1398
-
-
McGraw, D.W.1
Elwing, J.M.2
Fogel, K.M.3
Wang, W.C.H.4
Glinka, C.B.5
Mihlbachler, K.A.6
Rothenberg, M.E.7
Liggett, S.B.8
-
25
-
-
85047694597
-
q receptor signaling via phospholipase C underlies the airway beta-agonist paradox
-
DOI 10.1172/JCI200318193
-
McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 2003;112:619-626. (Pubitemid 38056346)
-
(2003)
Journal of Clinical Investigation
, vol.112
, Issue.4
, pp. 619-626
-
-
McGraw, D.W.1
Almoosa, K.F.2
Paul, R.J.3
Kobilka, B.K.4
Liggett, S.B.5
-
26
-
-
38049005296
-
The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study
-
Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008;21:134-141.
-
(2008)
Pulm Pharmacol Ther
, vol.21
, pp. 134-141
-
-
Hanania, N.A.1
Singh, S.2
El-Wali, R.3
Flashner, M.4
Franklin, A.E.5
Garner, W.J.6
Dickey, B.F.7
Parra, S.8
Ruoss, S.9
Shardonofsky, F.10
-
27
-
-
0025223381
-
Regular inhaled beta-agonist treatment in bronchial asthma
-
Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, Yates DM, Lucas MK, Herbison GP. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-1396.
-
(1990)
Lancet
, vol.336
, pp. 1391-1396
-
-
Sears, M.R.1
Taylor, D.R.2
Print, C.G.3
Lake, D.C.4
Li, Q.Q.5
Flannery, E.M.6
Yates, D.M.7
Lucas, M.K.8
Herbison, G.P.9
-
29
-
-
3142741559
-
Adverse effects of short-acting beta-agonists: Potential impact when anti-inflammatory therapy is inadequate
-
DOI 10.1111/j.1440-1843.2004.00557.x
-
Wraight JM, Smith AD, Cowan JO, Flannery EM, Herbison GP, Taylor DR. Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. Respirology 2004;9:215-221. (Pubitemid 38937395)
-
(2004)
Respirology
, vol.9
, Issue.2
, pp. 215-221
-
-
Wraight, J.M.1
Smith, A.D.2
Cowan, J.O.3
Flannery, E.M.4
Herbison, G.P.5
Taylor, D.R.6
-
30
-
-
53049089304
-
Management of beta-agonist overuse: Why and how?
-
Taylor DR, Hannah D. Management of beta-agonist overuse: Why and how? J Allergy Clin Immunol 2008;122:836-838.
-
(2008)
J Allergy Clin Immunol
, vol.122
, pp. 836-838
-
-
Taylor, D.R.1
Hannah, D.2
-
31
-
-
0013974629
-
Iatrogenic asthma associated with adrenergic aerosols
-
Keighley JF. Iatrogenic asthma associated with adrenergic aerosols. Ann Intern Med 1966;65:985-995.
-
(1966)
Ann Intern Med
, vol.65
, pp. 985-995
-
-
Keighley, J.F.1
-
32
-
-
0014530683
-
The adverse effect of adrenergic aerosols in bronchial asthma
-
Eisenstadt WS, Nicholas SS. The adverse effect of adrenergic aerosols in bronchial asthma. Ann Allergy 1969;27:283-288.
-
(1969)
Ann Allergy
, vol.27
, pp. 283-288
-
-
Eisenstadt, W.S.1
Nicholas, S.S.2
-
33
-
-
0026093711
-
Dose reduction of beta-agonists in asthma
-
Sears MR. Dose reduction of beta-agonists in asthma. Lancet 1991;338:1331-1332.
-
(1991)
Lancet
, vol.338
, pp. 1331-1332
-
-
Sears, M.R.1
|